Lyell Immunopharma, Inc. LYEL
16.86 USD +0.11 (+0.66%)
At closeNov 11, 2026, 4:00 PM EST
16.86 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
16.28 Day range 17.60
7.20 52-week range 45.00
- YTD
- -45.22%
- 1 year
- -2.26%
News
seekingalpha.com Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Lyell Immunopharma, Inc. ( LYEL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 4:00 PM EST Company Participants Lynn Seely - Principal Executive Officer, President, CEO & Director…
marketbeat.com Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have…
seekingalpha.com Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost Lyell Immunopharma is upgraded to “Buy” as pivotal ronde-cel CAR-T programs advance in relapsed/refractory large B-cell lymphoma [r/r LBCL]. LYEL secured $80 million in private placement, extending…
benzinga.com Lyell Immunopharma Q3 EPS $(1.86) Beats $(2.06) Estimate, Sales $3.000K Beat $2.333K Estimate Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(2.06) by 9.71 percent. This is a 12.68 percent increase over losses of…
globenewswire.com Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…
benzinga.com Lyell Immunopharma Announces ~$80M Private Placement Of 7.4M Shares At $10.77/Share The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.The financing…- benzinga.com Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients…
globenewswire.com Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
globenewswire.com Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients…
globenewswire.com Lyell Immunopharma To Participate in November Investor Events SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…
zacks.com Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts…
globenewswire.com Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen…- benzinga.com Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today…
globenewswire.com Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen…
benzinga.com This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…
benzinga.com Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36 Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.
benzinga.com B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44 B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.
defenseworld.net Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat.com reports.…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The market value of their outstanding shares is at $89.0 million. Innovative Eyewear (NASDAQ:LUCY) stock rose…
zacks.com Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 176% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is questionable,…
globenewswire.com Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…- benzinga.com Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target Citizens analyst Reni J. Benjamin reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Market Outperform and maintains $34 price target.
seekingalpha.com Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily…
benzinga.com Lyell Immunopharma Announces Data From Its Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-cell Lymphoma Shows Manufacturing Success Rate Of 97% Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, is announcing…
globenewswire.com Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration…
seekingalpha.com Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
benzinga.com HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.
benzinga.com Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update on Lyell Immunopharma Inc. (NASDAQ: LYEL) stock is up on Monday as the company is providing an update on the safety profile of its LYL273 treatment in a Phase 1 clinical trial for relapsed or…
benzinga.com Lyell Immunopharma Issues Colorectal Cancer Drug Safety Update Lyell Immunopharma reports improved safety data for LYL273 in metastatic colorectal cancer and advances study to Phase 1/2 design.- benzinga.com Lyell Immunopharma Issues LYL273 Safety Profile Update In Its Ongoing U.S. Phase 1 Clinical Trial In Patients With Relapsed Or Refractory Metastatic Colorectal Cancer Gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxisThe maximum tolerated dose has not yet been determinedNo difference is observed in…
globenewswire.com Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion SOUTH SAN FRANCISCO, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor…- benzinga.com Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today…
benzinga.com HC Wainwright & Co. Reiterates Buy on Lyell Immunopharma, Maintains $45 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $45 price target.
benzinga.com Earnings Scheduled For May 6, 2026 
benzinga.com This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts changed outlook on top stocks. See rating changes on NKE, SMPL, WSR, NTNX, and AES. Check analyst views before buying NKE.
benzinga.com This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Top Wall Street analysts changed outlook on top names. Initiations & upgrades noted. For full changes, see analyst ratings page.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- benzinga.com ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
- benzinga.com Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session